产品介绍 评论(0)
宿主来源
Mouse抗原名称
TIGIT分子别名
T-cell immunoreceptor with Ig and ITIM domains; V-set and immunoglobulin domain-containing protein 9; V-set and transmembrane domain-containing protein 3; VSIG9; VSTM3细胞定位
Cell membraneAccession
Q495A1克隆号
S-R730抗体类型
Mouse mAb抗体同种型
IgG2a,k反应种属 ?
Hu阳性样本
Human PBMC纯化方式
Protein A浓度
0.2 mg/ml标记
PE性状
Liquid缓冲体系
PBS, 1% BSA, 0.3% Proclin 300
储存条件
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用
FCM
稀释度
应用 稀释度 推荐种属 FCM 5μl per million cells in 100μl volume Hu
TIGIT (T cell immunoglobulin and ITIM domain) is an inhibitory receptor expressed on lymphocytes, including natural killer (NK) cells and various subsets of T cells such as CD4+ T cells, CD8+ T cells, and regulatory T cells. It was discovered in 2009 through genome-wide analysis aiming to identify proteins containing domain structures typical for immunomodulatory receptors. TIGIT consists of one extracellular immunoglobulin variable domain, a type I transmembrane domain, and a short intracellular domain with one immunoreceptor tyrosine-based inhibitory motif (ITIM) and one immunoglobulin tyrosine tail (ITT)-like motif. Its main ligand is CD155, also known as poliovirus receptor (PVR), but it can also bind to CD112 and CD113 with lower affinity. TIGIT plays a significant role in down-regulating T cell and NK cell functions by interacting with these ligands expressed on antigen-presenting cells or tumor cells. This interaction inhibits immune cell responses at multiple steps of the cancer-immunity cycle, such as impairing T cell priming by dendritic cells, preventing tumor cell killing by NK cells and cytotoxic T cells, and enhancing the immune suppressive activity of regulatory T cells. Therefore, TIGIT has emerged as a major target in cancer immunotherapy. Several monoclonal antibodies that block the inhibitory activity of human TIGIT have been developed, and clinical trials are ongoing to investigate TIGIT blockade as a monotherapy or in combination with anti-PD1/PD-L1 antibodies for the treatment of patients with advanced solid malignancies.
流式分析
Flow cytometric analysis of Human TIGIT expression on Human PBMC. Human PBMC (peripheral blood mononuclear cells) were stained with Brilliant Violet 421™ Mouse Anti-Human CD4 Antibody and either PE Mouse IgG2a, κ Isotype Control (Left panel) or PE Mouse Anti-Human TIGIT Antibody (Right panel) at 5 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.







评论(0)